×
Log In Create an Account
  • Home
  • About ECOS
  • Events
    • ECOS 2021
    • ECOS 2019
    • Cardio-oncology Calendar
  • Online Courses
    • Essentials of Cardio-oncology
    • Webcasts
    • IO Primers
  • Contact
 Sections
  • Imaging guidelines in cardio-oncology
  • Revolutionising cancer care with immunotherapy
  • Cardiac complications of checkpoint inhibitor therapy
  • Revolutionising cancer care with immunotherapy

    Friday 18 October 2019
    16:00 - 17:00 CEST | 10:00 - 11:00 EDT

     

    Sign up here to be notified when this webcast is available online for viewing and CME credit.

     

    Chair

    Javid Moslehi, MD
    Vanderbilt University Medical Center
    Nashville, TN, USA


    Faculty

     

    Sebastian Szmit, MD, PhD
    Centre of Postgraduate Medical Education
    Warsaw, Poland

    Alison Macklin, RN, BSc
    University College London Hospitals NHS Foundation Trust
    London, UK

     
    Overview

    In this multidisciplinary case-based panel discussion, experts in cardiology, oncology, and nursing care will share their approaches to managing the cardiovascular needs of patients undergoing treatment with cancer immunotherapies.


    Learning objectives

    Upon completion of this activity, participants will be better able to:

    • Identify the potential cardiovascular effects of cancer immunotherapies
    • Implement guidelines for risk stratification, monitoring, and toxicity management

     

    Registration

    Registration is now closed.

     

    Target audience

    This activity is primarily intended for clinicians who have special interest in the cardiovascular needs of patients with cancer, including cardiologists, oncologists, nurses, and other members of the multidisciplinary cardio-oncology team. 


    Financial disclosures

    Javid Moslehi
    Consultancy: Acceleron, Ariad, BMS, Daiichi Sankyo, Deciphera, Heat Biologics, Incyte, Ipsen, Myokardia, Novartis, Pharmacyclics, Pfizer, Regeneron, Redux Therapeutics, Rgenix, StemCentRx, Takeda/Millennium, Vertex, Verastem.
    Research grants: BMS, Pfizer.
    Shares: Redux Therapeutics.

    Sebastian Szmit
    Speakers’ Bureau: Angelini, Berlin-Chemie, BMS, Janssen-Cilag, Ibsen, Pfizer, Polpharma, Roche, Teva.

    Alison Macklin has no relevant financial relationships to disclose.

    Staff at Siyemi Learning have no relevant financial relationships to disclose.


    Continuing medical education

    Siyemi Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Siyemi Learning designates this live activity for 1 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

     


    Commercial support

    The ECOS 2019 meeting was supported by an independent medical educational grant from Novartis and in-kind support for the pre-conference workshop was provided by GE Healthcare.


    How to earn your CME credit

    At the end of the live webcast you will be required to complete a short post-test, you will then be directed to the ECOS website where you will be able to complete the evaluation and download your CME certificate.

    Please contact us at cme@cme-cpd.org with any questions or concerns.

    Sign up here to be notified when this webcast is available online for viewing and CME credit.

  •  

     

 
Follow Us
 
 
 

The University of Manchester Innovation Centre (UMIC)

Arch 29, North Campus Incubator
Sackville Street
Manchester M60 1QD
United Kingdom
+44 161 408 6084 
 info@cme-cpd.org
Privacy statement | Terms and conditions. Unless explicitly stated, all material © 2018 CME-CPD Academy
CME-CPD Academy is a division of Siyemi Limited, incorporated in England and Wales, 5883995.